Ferring Pharma regains rights to DDAVP portfolio

22 October 2014

Privately-held Switzerland-headquartered Ferring Pharmaceuticals says it has acquired DDAVP (desmopressin acetate) from French pharma major Sanofi (Euronext: SAN). Ferring is the original developer of the drug desmopressin and has a long-standing history in peptide-based specialty care.

"The return of DDAVP to its roots at Ferring is a welcome addition to our portfolio of products and affirms our commitment to supporting a wide range of disorders with high unmet medical need," said Aaron Graff, president and chief operating office of Ferring Pharmaceuticals. "As a result of this acquisition, distribution of DDAVP will be transferred from Sanofi to Ferring immediately," he noted.

DDAVP is available in the following formulations: DDAVP Tablets, DDAVP Nasal Spray, DDAVP Rhinal Tube and DDAVP Injection, all of which are approved by the US Food and Drug Administration. Desmopressinis the medicine commonly used to treat diabetes insipidus and bedwetting.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK